179 related articles for article (PubMed ID: 11194214)
21. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.
Rosenstock J; Hassman DR; Madder RD; Brazinsky SA; Farrell J; Khutoryansky N; Hale PM;
Diabetes Care; 2004 Jun; 27(6):1265-70. PubMed ID: 15161773
[TBL] [Abstract][Full Text] [Related]
22. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.
Goldberg RB; Einhorn D; Lucas CP; Rendell MS; Damsbo P; Huang WC; Strange P; Brodows RG
Diabetes Care; 1998 Nov; 21(11):1897-903. PubMed ID: 9802740
[TBL] [Abstract][Full Text] [Related]
23. Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control.
Raskin P; Lewin A; Reinhardt R; Lyness W;
Diabetes Obes Metab; 2009 Oct; 11(10):947-52. PubMed ID: 19531054
[TBL] [Abstract][Full Text] [Related]
24. Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes.
Damsbo P; Marbury TC; Hatorp V; Clauson P; Müller PG
Diabetes Res Clin Pract; 1999 Aug; 45(1):31-9. PubMed ID: 10499883
[TBL] [Abstract][Full Text] [Related]
25. Repaglinide in combination therapy with metformin in Type 2 diabetes.
Moses R
Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 4():S136-9. PubMed ID: 10522839
[TBL] [Abstract][Full Text] [Related]
26. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.
Lund SS; Tarnow L; Frandsen M; Nielsen BB; Hansen BV; Pedersen O; Parving HH; Vaag AA
BMJ; 2009 Nov; 339():b4324. PubMed ID: 19900993
[TBL] [Abstract][Full Text] [Related]
27. Dose titration of repaglinide in patients with inadequately controlled type 2 diabetes.
Kølendorf K; Eriksson J; Birkeland KI; Kjellström T; Hreidarsson AB
Diabetes Res Clin Pract; 2004 Apr; 64(1):33-40. PubMed ID: 15036825
[TBL] [Abstract][Full Text] [Related]
28. Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone.
Jovanovic L; Hassman DR; Gooch B; Jain R; Greco S; Khutoryansky N; Hale PM
Diabetes Res Clin Pract; 2004 Feb; 63(2):127-34. PubMed ID: 14739053
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes.
Strange P; Schwartz SL; Graf RJ; Polvino W; Weston I; Marbury TC; Huang WC; Goldberg RB
Diabetes Technol Ther; 1999; 1(3):247-56. PubMed ID: 11475269
[TBL] [Abstract][Full Text] [Related]
30. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.
Derosa G; Mugellini A; Ciccarelli L; Crescenzi G; Fogari R
Clin Ther; 2003 Feb; 25(2):472-84. PubMed ID: 12749508
[TBL] [Abstract][Full Text] [Related]
31. Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
Ma J; Liu LY; Wu PH; Liao Y; Tao T; Liu W
J Diabetes Res; 2014; 2014():294017. PubMed ID: 24772445
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
Raskin P; Klaff L; McGill J; South SA; Hollander P; Khutoryansky N; Hale PM;
Diabetes Care; 2003 Jul; 26(7):2063-8. PubMed ID: 12832314
[TBL] [Abstract][Full Text] [Related]
33. Effect of Switching from Sulphonylurea to Repaglinide Twice or Three Times Daily for 4 Months on Glycemic Control in Japanese Patients with Type 2 Diabetes.
Kamiyama H; Aoki K; Nakajima S; Shinoda K; Kamiko K; Taguri M; Terauchi Y
Intern Med; 2016; 55(13):1697-703. PubMed ID: 27374668
[TBL] [Abstract][Full Text] [Related]
34. The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy naïve Type 2 diabetes: a placebo-controlled, multicentre study.
Bech P; Moses R; Gomis R
Qual Life Res; 2003 Jun; 12(4):413-25. PubMed ID: 12797714
[TBL] [Abstract][Full Text] [Related]
35. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting.
Mafauzy M
Diabetes Res Clin Pract; 2002 Oct; 58(1):45-53. PubMed ID: 12161056
[TBL] [Abstract][Full Text] [Related]
36. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.
Johansen OE; Birkeland KI
Am J Cardiovasc Drugs; 2007; 7(5):319-35. PubMed ID: 17953471
[TBL] [Abstract][Full Text] [Related]
37. [Antidiabetic drug at every meal. Repaglinide is especially recommended for slender type 2 diabetic patients].
Landgraf R
MMW Fortschr Med; 2000 Jul; 142(28-29):29-30. PubMed ID: 10959157
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of repaglinide added to sitagliptin in Japanese patients with type 2 diabetes: A randomized 24-week open-label clinical trial.
Nishimura A; Usui S; Kumashiro N; Uchino H; Yamato A; Yasuda D; Nagasawa K; Okubo M; Mori Y; Hirose T
Endocr J; 2016 Dec; 63(12):1087-1098. PubMed ID: 27647480
[TBL] [Abstract][Full Text] [Related]
39. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.
Bakiner O; Ertorer ME; Bozkirli E; Tutuncu NB; Demirag NG
Acta Diabetol; 2009 Mar; 46(1):63-5. PubMed ID: 18825302
[TBL] [Abstract][Full Text] [Related]
40. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.
Culy CR; Jarvis B
Drugs; 2001; 61(11):1625-60. PubMed ID: 11577798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
